Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03972774 · ClinicalTrials.gov registry record · NA

Assessment of Patients With suspeCted Coronary Artery Disease by Coronary calciUm fiRst strATegy vErsus Usual Care Approach.

A NA study of Coronary Artery Disease, sponsored by Intermountain Health Care.

Recruiting
Registry status
NA
Development phase
2,500
Enrollment target
1
Study location

NCT03972774: Recruiting NA study of Coronary Artery Disease, sponsored by Intermountain Health Care.

NCT03972774 is a NA study of Coronary Artery Disease that is actively recruiting participants, run by Intermountain Health Care. The registered enrollment target is 2,500 participants, above the 1,276-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (96% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03972774, a NA study of Coronary Artery Disease, is actively recruiting participants, sponsored by Intermountain Health Care.

RECRUITING
Registry status
NA
Development phase
2,500 participants
Enrollment target
1
Study location

Study Summary

The cost of medical care in the United States far exceeds that of all other advanced economies and continues to accelerate at a rate unacceptable to our society, due primarily to the high costs of new imaging technologies and novel drugs (1). Cardiac positron emission tomography (PET) imaging is a powerful new modality for the non-invasive detection of provocable coronary ischemia in patients with low to intermediate-risk chest pain or its equivalent. Intermountain Medical Center (IMC) is performing approximately 6000 clinical cardiac PET scans annually. However, cardiac PET scans are expensive (i.e., billed at \>$5,000/scan, average receivable revenue $1500-$2000/scan). Coronary artery calcium (CAC) is a sensitive marker of coronary atherosclerosis. A CAC scan (CACS), performed by multislice computed tomography (CT), is a relatively inexpensive (\~$70-$150/scan), low-radiation dose test that marks the presence of coronary atherosclerotic plaque. The absence of CAC has been shown to be associated with very low coronary risk. ACCURATE will test whether a CAC-first strategy (i.e., risk stratification, when CAC ≤ 1, to medical management or to cardiac PET stress testing), performed routinely in symptomatic patients presenting for evaluation of possible coronary artery disease (CAD) prior to the cardiac PET stress test, can be used as a gatekeeper for progression to the expensive rubidium-PET stress (regadenoson) perfusion scan and be a major cost-saver without adversely affecting patient care or outcomes. Routinely, qualifying patients undergo CACS when they present for evaluation of possible but unknown CAD status and are referred for cardiac PET stress testing. In ACCURATE, those with CACS≤1 will then be consented and randomized to either a cardiac PET stress test strategy or a non-PET-driven medical care strategy. Subjects randomized to the cardiac PET stress test strategy will receive appropriate subsequent care depending on the outcome of the cardiac PET scan (i.e

Primary Outcome

Routine cardiac PET stress test strategy will result in significantly fewer major adverse cardiac endpoint (MACE) outcomes (defined as coronary death, non-fatal myocardial infarction, cardiac arrest, or ischemia driven revascularization) at 1 year compared with a a CAC-first strategy.

Conditions Studied

Interventions

  • DIAGNOSTIC_TEST PET Stress Test
  • OTHER Non-PET Medical Management

Study Locations (1)

Utah

  • Intermountain Healthcare Hospitals and Clinics - Salt Lake City

Trial Details

FieldValue
Enrollment Target 2,500 participants
Start Date 2019-11-19
Est. Completion 2029-11
Phase NA
Intermountain Health Care

85 total trials

What NCT03972774 shows while recruiting

NCT03972774 is an interventional study that assigns participants to a tested intervention. Its 2,500 participants enrollment target places it among the larger protocols in the corpus, above the 1,276-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (96% higher).

The record links to 1 condition, with Coronary Artery Disease appearing as the primary indexed condition, and to 2 interventions - of which PET Stress Test is the first listed.

NCT03972774 reports a single indexed study location in Utah.

Frequently Asked Questions

What is clinical trial NCT03972774 about?

NCT03972774 is a clinical study titled "Assessment of Patients With suspeCted Coronary Artery Disease by Coronary calciUm fiRst strATegy vErsus Usual Care Approach.". The cost of medical care in the United States far exceeds that of all other advanced economies and continues to accelerate at a rate unacceptable to our society, due primarily to the high costs of new imaging technologies and novel drugs (1). Cardiac positron emission tomography (PET) imaging is a p...

What is the current status of trial NCT03972774?

This trial is currently recruiting. It is a NA study. The enrollment target is 2,500 participants. The study started on 2019-11-19. Estimated completion is 2029-11.

What conditions does trial NCT03972774 study?

This clinical trial studies the following conditions: Coronary Artery Disease.

What interventions are being tested in trial NCT03972774?

The interventions under investigation include: PET Stress Test (DIAGNOSTIC_TEST), Non-PET Medical Management (OTHER).

Who is sponsoring clinical trial NCT03972774?

This trial is sponsored by Intermountain Health Care, which has 85 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03972774 being conducted?

This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Coronary Artery Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03972774's enrollment target sits among peer trials

2,500 22nd of 219 higher than 197 of 219 other Coronary Artery Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Coronary Artery Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00001160 · 2,500 participants

    Studies on Tumors of the Thyroid

  • NCT01904188 · 2,500 participants

    Clinical Microbial Species & Antibiotic Resistance ID in ED Patients Presenting With Infection - is Rapid ID Possible & Accurate?

  • NCT02257229 · 2,500 participants

    Prospective Evaluation of Treatment for Clubfoot

  • NCT02530658 · 2,500 participants

    Next Generation Sequencing of Normal Tissues Prospectively in Pediatric Oncology Patients

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03972774, the US trial registry maintained by the National Library of Medicine. NCT03972774 (large enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.